Lynnette C. Fallon - 19 May 2026 Form 4 Insider Report for ClearPoint Neuro, Inc. (CLPT)

Reporting relationship: Director
Issuer ticker: CLPT
Reported as of: 19 May 2026
Net transaction value: -$56,714
SEC form: 4
Accepted by SEC: 21 May 2026, 16:30:19 UTC
Prior SEC filing: 05 Jun 2025
Next SEC filing: 26 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Danilo D'Alessandro, by Power of Attorney for Lynnette C. Fallon

Key filing fact

Lynnette C. Fallon filed Form 4 for ClearPoint Neuro, Inc. (CLPT) on 21 May 2026.

Key facts

This page summarizes Lynnette C. Fallon's Form 4 filing for ClearPoint Neuro, Inc. (CLPT).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 21 May 2026, 16:30.

Change

Previous filing in this sequence was filed on 05 Jun 2025.
Current net transaction value: -$56,714.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001195654 Primary reporting owner

FALLON LYNNETTE C

Relationship: Director
Address: C/O CLEARPOINT NEURO, INC., 120 S. SIERRA AVE., SUITE 100, SOLANA BEACH
Signature: /s/ Danilo D'Alessandro, by Power of Attorney for Lynnette C. Fallon
Signature date: 21 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CLPT transaction

Common Stock

Options Exercise

Transaction value
Shares: +12,417
Change %: +30%
Price
Shares after: 53,318
Date: 19 May 2026
Ownership: Direct
Footnotes: F1

CLPT transaction

Common Stock

Sale

Transaction value: $56,714
Shares: -5,091
Change %: -9.5%
Price: $11.14
Shares after: 48,227
Date: 20 May 2026
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLPT transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -12,417
Change %: -100%
Price
Shares after: 0
Date: 19 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,417
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

Footnote F2

This sale of shares was made pursuant to a Rule 10b5-1 trading plan to cover the tax liability incident to the vesting of 12,417 shares on May 19, 2026 under a restricted stock unit granted to the director on May 22, 2025.

Footnote F3

Represents a weighted average sales price per share. The shares were sold at prices ranging from $11.04 to $11.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.